Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 11c
August 4, 2022 4:01 PM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.68), $0.11 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $32.41 million versus the consensus estimate of $49.23 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
... More